ACTAVIS has announced a
settlement agreement with Shire
Pharmaceuticals, resolving patent
litigation over Actavis’ generic
version of Intuniv (guanfacine
hydrochloride) for the treatment
of Attention Deficit Hyperactivity
Disorder.
The FDA approved Actavis’ version
last Oct, and under the terms of the
deal Actavis can launch a generic
version of Intuniv on 01 Dec 2014.
Shire will receive a 25% royalty on
Actavis’ gross profits from the first
six months of sales.The above article was sent to subscribers in Pharmacy Daily's issue from 26 Apr 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Apr 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.